These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. Ogino MT, Dankner WM, Spector SA. J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579 [Abstract] [Full Text] [Related]
5. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, Pearson D, Gershon A, McSherry GD, Abrams EJ, Schliozberg J, Sullivan JL. N Engl J Med; 1997 Jun 12; 336(24):1704-12. PubMed ID: 9182213 [Abstract] [Full Text] [Related]
6. Zidovudine resistance of human immunodeficiency virus. Richman DD. Rev Infect Dis; 1990 Jun 12; 12 Suppl 5():S507-10; discussion S510-2. PubMed ID: 2201072 [Abstract] [Full Text] [Related]
8. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. Richman DD, Grimes JM, Lagakos SW. J Acquir Immune Defic Syndr (1988); 1990 Jun 12; 3(8):743-6. PubMed ID: 2114476 [Abstract] [Full Text] [Related]
14. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. McKinney RE, Maha MA, Connor EM, Feinberg J, Scott GB, Wulfsohn M, McIntosh K, Borkowsky W, Modlin JF, Weintrub P. N Engl J Med; 1991 Apr 11; 324(15):1018-25. PubMed ID: 1672443 [Abstract] [Full Text] [Related]
15. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H. JAMA; 1996 Jul 10; 276(2):111-7. PubMed ID: 8656502 [Abstract] [Full Text] [Related]
17. Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations. Marschner IC, Mayers DL, Erice A, Smeaton L, Johnson VA, Richman DD, Reichelderfer P, Japour AJ. J Clin Microbiol; 1997 Mar 10; 35(3):756-8. PubMed ID: 9041428 [Abstract] [Full Text] [Related]
19. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P. J Infect Dis; 1994 Apr 10; 169(4):713-21. PubMed ID: 8133085 [Abstract] [Full Text] [Related]
20. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. Edlin BR, Weinstein RA, Whaling SM, Ou CY, Connolly PJ, Moore JL, Bitran JD. J Infect Dis; 1992 May 10; 165(5):793-8. PubMed ID: 1349031 [Abstract] [Full Text] [Related] Page: [Next] [New Search]